The Phase I trail showed encouraging results, but that’s still a long way from a working vaccine that everyone can take. Biotech company Moderna reported positive Phase 1 COVID-19 vaccine trial results this morning, boosting its stock shares by 25% and drumming up a media cyclone of excitement. What does this actually mean, though? Not as much as you hope. Read Full Story

Moderna reported positive Phase I testing results for its COVID-19 vaccine and will begin Phase III testing it on 30,000 humans in two weeks. News! Moderna reported positive Phase I testing results for its COVID-19 vaccine and will begin Phase III testing it on 30,000 humans in two weeks. (Separate Phase II trials are underway.) “No matter how you slice this, this is good news,” Dr. Anthony Fauci, our national bearer of bad news, told the Associated Press. Read Full Story

Johnson & Johnson has released data from its global Phase 3 clinical trial today. Many COVID-19 vaccines have name brands attached them, but one of them has drawn a lot of attention lately. Johnson & Johnson released data from its global Phase 3 clinical trial today. Here’s what to know: Read Full Story

But even if the EUA is granted, it will be a while before the average American can get the vaccine. Moderna today will officially file for emergency use authorization from the U.S. Food and Drug Administration for its COVID-19 vaccine. The company made the announcement alongside updating its vaccine efficacy rating from its phase 3 trial. Read Full Story

To make sure a vaccine works for everyone, everyone needs to be in the trials. At least 10 COVID-19 vaccines are currently in the final phase of their trials, where the vaccine is given to thousands of people to test its safety and efficacy. But as the quest for a coronavirus vaccine continues, experts say there’s still an issue with how diverse these trials are, which could impact how effective a vaccine is for everyone. Read Full Story

“There’s no case where we get much below the current death rate, which is about 500 deaths a day, but there’s a significant risk we go back up to the even 2,000 a day.” COVID-19 vaccine trials are well under way, but Bill Gates is not optimistic that phase III of these trials, which measures the efficacy and safety of a vaccine in a wide group of users, will be successful before the end of the year. Read Full Story

Initial tests have been promising, but what happens if none of the trials pans out? The race for a COVID-19 vaccine is unprecedented: 198 potential vaccines are now in development, and that development is happening faster than it ever has in history. Moderna, for example, finalized its vaccine just days after Chinese researchers released the genetic sequence of the new coronavirus in January. Two months later, the first volunteer was dosed with the vaccine. Last week, the company published positive Phase I trial results showing that the vaccine seems safe and generates an immune response; days later, Oxford University researchers published similarly promising results. Read Full Story

This Monday it was announced that, according to the results produced during the third phase of clinical trials, Sputnik V does have a high percentage of effectiveness.

Moderna's coronavirus vaccine candidate entered its next phase of human trials on Monday. The company hopes to have results by Thanksgiving.

Biotech company Moderna said it plans to start phase 2 trials with 600 participants shortly.